Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744886 | 0.91 | GRM2 (0.47) | GRM2RAB9ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL14745005 | 0.87 | CYP3A4 (0.48) | GRM2RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL14744954 | 0.87 | GRM2 (0.51) | GRM2RAB9ASMN1; SMN2 | |
| SCHEMBL14745371 | 0.84 | CYP3A4 (0.51) | GRM2CYP3A4 | |
| SCHEMBL14744671 | 0.84 | NPC1 (0.47) | GRM2RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14744793 | 0.83 | GRM2 (0.52) | GRM2RAB9ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL14744648 | 0.83 | GRM2 (0.64) | GRM2RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14744801 | 0.81 | CYP3A4 (0.52) | GRM2RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL23954519 | 0.78 | RAB9A (0.69) | GRM2RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14744633 | 0.78 | GRM2 (0.66) | GRM2RAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | GRM1, GRM3, GRM2 | GRM2 3/4885RAB9A 564/4885SMN1; SMN2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.